SEC Form 4 · accession 0001209191-17-064252
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barclay A Phillips
Officer — SVP & Chief Financial Officer
Period of report
Dec 6, 2017
Accepted (ET)
Dec 6, 2017 · 6:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $19.46 | Dec 6, 2017 | A | 250,000 | A | — | Nov 13, 2027 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The shares underlying this option will vest as to 25% of the shares on the first anniversary of the commencement of the Reporting Person's employment (which began on November 13, 2017) and as to an additional 1/48th of the shares monthly thereafter, subject to the Reporting Person's continued service through the applicable vesting dates.